scispace - formally typeset
G

Glenn M. Chertow

Researcher at Stanford University

Publications -  830
Citations -  94517

Glenn M. Chertow is an academic researcher from Stanford University. The author has contributed to research in topics: Kidney disease & Dialysis. The author has an hindex of 128, co-authored 764 publications receiving 82401 citations. Previous affiliations of Glenn M. Chertow include University of Groningen & Fresenius Medical Care.

Papers
More filters
Journal ArticleDOI

Risk factors of short-term mortality after acute nonvariceal upper gastrointestinal bleeding in patients on dialysis: a population-based study

Ju-Yeh Yang, +5 more
- 26 Apr 2013 - 
TL;DR: A profile of risk factors for 30-day mortality after ANVUGIB among patients on dialysis that was distinct from what had been reported in non-dialysis populations was identified.
Journal ArticleDOI

Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD

Niels Jongs, +12 more
- 17 Aug 2022 - 
TL;DR: Among patients with CKD and albuminuria treated with dapagliflozin, an acute reduction in eGFR (from baseline to 2 weeks) is not associated with higher rates of CKD progression and long-term efficacy and safety.
Journal ArticleDOI

Choroidopathy and kidney disease: a case report and review of the literature

Nirav Kamdar, +5 more
- 12 May 2009 - 
TL;DR: The patient was a 41 year-old Mexican American women who presented with a decrease in visual acuity along with periorbital and peripheral edema and improved considerably in hospital after treatment with corticosteroids.
Journal ArticleDOI

Fibroblast Growth Factor 23 Genotype and Cardiovascular Disease in Patients Undergoing Hemodialysis.

Tae Hwi Schwantes-An, +9 more
- 01 Jan 2019 - 
TL;DR: In this article, single-nucleotide polymorphisms (SNPs) in FGF23, alpha-klotho (KL), and FGFR4 were evaluated in proportional hazards regression models using adjudicated endpoints (all-cause and cardiovascular mortality, sudden cardiac death, and heart failure) as the outcome of interest.

Achievement of proposed NKF-K/DOQI Bone Metabolism and Disease targets Treatment with cinacalcet HCl in dialysis patients with uncontrolled secondary hyperparathyroidism

Sharon M. Moe, +12 more